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ABSTRACT 
In this work, we have introduced a carbon nanomaterial (nanodiamond), to bind with anticancer drug doxorubicin (DOX) with via  amide bond 
conjugation for cancer drug delivery and therapy. Nanodiamond (ND) was initially carboxylated by the surface modification along the 
treatment with strong alkaline solution (H2SO4:HNO3) and then activated the carboxyl moiety of ND with the addition of EDC.  Anticancer drugs 
were bound to the ND through a succession of chemical modifications by adipic acid dihydrazide (ADH). The ND-Drug conjugate was analyzed 
by Nuclear Magnetic Resonance (1H-NMR) Spectroscopy, Fourier Transform Infrared (FTIR) Spectroscopy and Mass Spectroscopy (MS), Atomic 
Force Microscopy (AFM), Particle size, Zeta potential, Drug release, SRB assay against MCF-7 cells, and DNA fragmentation. Spectroscopic 
analysis confirms the conjugation of nanodiamond with different anticancer drug. AFM photomicrograph represents the surface morphological 
features of ND-DOX conjugates. In- vitro investigation showed that ND-DOX conjugates have slow and sustained drug release characteristics. In-
vitro cytotoxicity studies, an enormous cytotoxic potential of ND-Drug conjugates were showed against cancer cell line.  Above all findings were 
suggested that the ND-DOX conjugates may be a potential inhibitor of MCF-7 cancer cells to act as a drug candidate. According to all these data it 
can be confirm that the ND-DOX conjugates could be an effective agent for drug delivery and could be promising in future for tumor targeting 
strategy.  
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INTRODUCTION 
As a major cause of mortality, cancer remains a global public 
health concern. To date, the most common treatment of 
cancer has been chemotherapy, the therapeutic effect of 
which is far from optimal due largely to the nonspecific 
toxicity of chemotherapeutics. That is why the idea of cancer 
nanotechnology is put forward, which provides a unique 
approach against cancer by applying nanotechnology in 
cancer management1, 2. Chemotherapy is a process for 
treating cancerous diseases; but due to improper selective 
recognition of cancerous and normal cells, there are various 
side effects are seen in patients during the chemotherapy. 
With the progress in nanotechnology, in the treatment of 
cancerous disease, drugs conjugated or adsorbed into 
nanocarriers presented various advantages related with free 
drugs, like controlled drug release, altered drug 
biodistribution, prolonged drug circulation in the blood, and 
anti-multidrug resistance; are now became keen topic for 
research 3, 4. 
Nanodiamond or diamond nanoparticles are diamonds 
having particle size range less than one micrometre. Nano 
scale-size diamond fragments are propitious components for 
research due to their comparably narrow and small size 
allocation, flexible surface complex and chemical dormancy, 
altogether which constitute them as affirmative elements for 
various biological and electronic applications5-8. In current 
research work, we investigate the effectively of ND-DOX 
conjugates against breast cancer cell line, and also explore 
the drug retention in cancer cell line. The anticancer drug 
substance bind effectively with the surface modified 
nanodiamond via amide bond. The resultant complex, ND-
DOX, was further characterized by different assay. 
Importantly, we show that ND-DOX conjugates enhance 
sensitivity of resistant of drug in breast cancer cells, possibly 
mediated via increased drug retention in the tumor cells. 
Additionally, it’s also posses the prolonged and sustained 
drug release mechanism from ND-DOX conjugates. This 
work suggests the use of nanodiamond as a promising and 
effective drug delivery platform for anticancer drug against 
tumor cells. 
MATERIALS 
Nanodiamond powder (ND), Adipic acid dihydrazide (ADH) 
was procured from Sigma Aldrich (USA). Doxorubicin (DOX) 
was obtained as generous gift sample from Dabur India 
Limited, Ghaziabad, India. N-hydroxysuccinimide (NHS), 
dialysis membrane, 1-ethyl-3-(3-dimethylaminopropyl) 
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carbodiimide hydrochloride (EDC-HCl), N, N’ Dicyclohexyl 
Carbodiimide (DCC), Pluronic F-68 were purchased from 
Himedia laboratories, Mumbai, India. Acetone, ethanol, 
concentrated HNO3, sulphuric acid, hydrochloric acid, 
isopropyl alcohol and acetonitrile purchased from Merck 
Limited, Mumbai, India. Other chemicals which are 
consumed are of investigative chemical grade and used as 
brought.  
METHODOLOGY  
Synthesis of carboxylated ND (ND-COOH) 
The commercially available synthesized nanodiamond 
powder having particle size of <10 nm, were carboxylated by 
following the standard procedure9. Primarily the obtained 
nanodiamond powder was treated with the mixture of H2SO4 
and HNO3 (3:1 v/v) at room temperature for 48 h and then 
diluted with the addition of deionized water and centrifuged 
at 900 rpm for 30 min to separate out the ND particles. The 
obtained particles were rinsed by using deionized H2O. Then 
obtained solution was again centrifuged at 900 rpm to 
separate out the ND particle, which was further heated at 
90ºC for 2 h in 0.1 M NaOH solution. Then ND sample was 
heated again with 0.1 M HCl for 2 h at 90ºC, and washed by 
using deionized water to solution became weakly acidic. The 
obtained carboxylated-NDs were separated and dried under 
vacuum for further procedure 9. 
Synthesis of activated nanodiamond 
Firstly, 50 mg of ND powder was dispersed in 10 ml of 
distilled water (5 mg/ml) and then 250 mg of EDC-HCl was 
added with continuous stirring (Remi, Mumbai, India) for 12 
h and maintain the pH 5.8 with the addition of 0.1N HCl. The 
EDC-HCl provides the effective activation of the carboxyl 
moiety of the NDs end group which enhances the attachment 
of NDs with another group of next chemical compound (-NH2 
moiety of the adipic acid dihydrazide). Subsequently 
addition of 125 mg of NHS into nanodiamond dispersion 
with constant rate of stirring and maintain the pH 5.8 with 
the addition of 0.1N HCl.  
Syntheses of ND-DOX conjugate 
To synthesize the different ND-DOX conjugate, the 
anticancer drugs (DOX) was conjugated with activated 
carboxylated NDs (ND-COOH). Primarily, the anticancer drug 
(DOX) was dissolved in aqueous system (distilled water) 
according to their solubility parameters.  DOX (50 mg) was 
dispersed in 10 ml of aqueous medium, and then the 
prepared drug solution was activated with the addition of 
DCC and NHS. Surfactant (Pluronic F-68) medium of 
different concentration (0.25%, 0.5% and 1%) was formed 
by dissolving Pluronic-F-68 in acetone. 10 ml of drug 
dispersion (DOX) and ND-COOD (5 mg/ml) was added in 
drop wise manner in alternating sequence into separate 
Pluronic-F-68 (surfactant) medium with continuous stirring 
for 12 h to formulate drug conjugated nanodiamond i.e. ND-
DOX conjugate. All the reaction mixtures were dialyzed to 
remove unreacted ND, DOX from all the formulated ND-DOX 
conjugate The obtained different ND-DOX was separated by 
membrane filter (0.45μm) and centrifuged at 15,000 rpm 
for 30 min (Remi, Mumbai, India). After centrifugation 
discarded the supernatant and lyophilized and preferred for 
subsequent analysis.   
Characterization parameters of ND-DOX conjugate 
The ND-DOX conjugate was prepared and authenticated by 
different spectroscopic instrumental methods i.e. nuclear 
magnetic resonance (1H-NMR) (Bruker AvII-400), and 
Fourier transform infrared (FTIR) (8400S, 
Shimadzu) spectroscopic technique. FTIR is most common 
technique used to determine the different functional group 
present in the prepared nanodiamond conjugate.  
Particle morphology, particle size characteristic and 
surface charge (zeta potential)  
The size of ND-DOX conjugate and the surface charge 
characteristics of synthesized ND-DOX conjugate were done 
by HORIBA SZ-100 series, (Horiba Scientific, Kyoto, Japan).  
The surface characteristics of prepared ND-DOX conjugate 
were examined by Variable Pressure Field Emission 
Scanning Electron Microscope (Supra 55, VP FE-SEM, Carl 
Zeiss). The application was done at various pressure 2-
133Pa with accelerating voltage 0.1 to 30kV.  The surface 
morphology of formulated ND-DOX conjugate was also be 
analyzed with Atomic Force Microscopic method (AFM) 
(Alpha300RA AFM, WITec, Germany). For taking AFM 
photomicrograph of the ND-DOX dispersion was spread on 
glass substrate on AC mode. 
Drug loading efficiency of ND-DOX conjugate 
The loading proficiency of different synthesized ND-DOX 
conjugate by HPLC system. The anticancer bioactive (DOX) 
conjugated nanodiamond were separately dispersed in 10 
ml of  PBS (pH 7.4) medium then the conjugate dispersed 
medium was filled in centrifuge tube and then centrifuged at 
15000 rpm in cooling centrifuge (C-24BL, Remi, Mumbai, 
India) for 5 min. Then after centrifugation the supernatant 
were taken out and analyzed by using high performance 
liquid chromatography (HPLC) (Shimadzu, Japan). The HPLC 
system consist reverse phase Cosmosil C18 column 
(4.6 mm × 250 mm, 5 µm, China) with UV detector was used 
to analyze the entrapment efficiency of prepared ND-DOX 
conjugate. The temperature of column should be maintained 
at 30 °C, for detection of UA content, methanol: phosphate 
buffer (pH 7.4) at (70:30 v/v) was taken as mobile phase 
with the flow rate 0.8 ml/min and detection of DOX was 
done at 485 nm. The amount of drug loaded in ND was 
calculated from unbound drug in the supernatant, the 
loading efficiency of ND-DOX conjugate was analysed. 
In-vitro release profile 
The in-vitro drug release characteristics of the prepared ND-
DOX conjugate were performed by modified dissolution 
technique. The prepared conjugate were placed separately 
in dialysis bag (Himedia Lab Limited, Mumbai, India) and 
dipped into the separate container containing 10 ml of 
phosphate buffer saline (PBS) having different pH range (pH 
7.4, 6.5 and 5.5) and the medium was stirred with the rate of 
100 rpm at 37±0.5°C. At a definite time interval an adequate 
quantity of the medium was taken out and replaced with the 
same quantity of the fresh PBS medium to maintain the sink 
condition. The collected medium was centrifuged at 5000 
rpm for 15 min, subsequently the supernatant was taken out 
from the centrifuge tube and analyzed by HPLC system as 
previously described to carry out the amount of percentage 
cumulative drug released from ND-DOX conjugate. 
Hemolytic toxicity 
For hemolytic activity, whole human blood was amassed and 
collected in a collection vial from authorized pathology 
centre as denoted in Bhadra et al., 200510. Firstly human 
blood was centrifuged at 10,000 rpm for 15 min for 
complete separation of RBC and plasma. The plasma was 
discarded and RBC was taken for further procedure. The red 
blood corpuscle (RBCs) (1ml) was incubated separately with 
10 ml of phosphate buffer solution pH 7.4 (taken as 100% 
hemolytic standard). In this hematocrit solution the ND-DOX 
conjugate and unmodified anticancer drugs (DOX), were 
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added separately on hematocrit solution. The collection tube 
was allowed to stand for 1-2 h at 37°C, after that the ND-DOX 
conjugate in hematocrit mixture was centrifuged at 5000 
rpm for 10 min, and then the absorbance was taken of 
supernatant at 540 nm to optimize the effect of ND-DOX 
conjugate and plain (unmodified) drugs against RBCs, which 
was useful to predict the percentage hemolysis.  
SRB (sulforhodamine B) assay 
Initially the cell line were grown in the RPMI 1640 medium 
containing fetal bovine serum (FBS 10%) and L-glutamine 
(2mM) further cell were inoculated on 96 well microtiter 
well plate containing 100µl plating densities. After it 
microtiter plates were incubated at temperature 37°C, 5% 
CO2, 100% relative humidity and 95% air for 24 h before 
addition of formulations (i.e. ND-DOX conjugate, ND, plain 
anticancer drugs). Firstly conjugate were dissolved in 
dimethyl sulfoxide at 100 mg/ml further diluted to 1mg/ml 
using distilled and kept frozen before use. Aliquots for 
frozen concentrate diluted to 100μg/ml, 200μg/ml, 
400μg/ml and 800μg/ml during the addition of different 
conjugate with total medium consisting test articles. Final 
concentration of 10μg/ml, 20μg/ml, 40μg/ml and 80μg/ml 
was prepared by adding 10µl of different dilutions in 
microtiter wells consisting 90µl of medium. Plates were 
incubated after compound was added at standard conditions 
for 48 h and assay was performed with cold trichloroacetic 
acid (TCA) and incubated at 4°C for 60 minutes further the 
supernatant was discarded and plates were cleaned. After 
than all the wells were treated with sulforhodamine B (SRB) 
solution (50µl) at 0.4 % (w/v) in 1 % acetic acid and 
incubated at room temperature for 30 minutes. The plates 
were dried and the absorbance was noted at 540 nm with 
690 nm reference wavelength. Percent growth of cell was 
determined against control wells by plate-by-plate basis and 
further calculated as: [Ti/C] x 100 %. Finally the morphology 
of MCF-7 cell lines was determined by the light 
microscope11. 
DNA fragmentation analysis 
Genomic DNA with low-molecular-weight was extracted as 
detailed previously (Yawata, 1998; 
http://www.abcam.com/protocols/apoptosis-dna-
fragmentation-analysis-protocol) 12. A breast cancer cell 
(MCF-7) was firstly treated with ND-DOX conjugate then cell 
was lysed in a buffer solution consisting 5mM EDTA 
(ethylene diamine tetra acetic acid), 5mM of  pH 7.5 Tris HCl 
and 0.5% Triton X-100 intended for an about 30 min on ice. 
The prepared lysate media were vortexed by vortex shaker 
and then centrifuged at 30,000 for about 20mins. The 
fragmented DNA present in the supernatant was reacted 
with RNAse, after then treated with proteinase K digestion, 
and added on the mixture of phenol, chloroform and isoamyl 
alcohol in different volume concentration (25:24:1) 
extraction and isopropanol precipitation. The separation of 
DNA was carried out through agarose gel (1.5%), and then 
stained by using ethidium bromide solution (0.1μg/ml) and 
interpretation of fragmentation can be visualized under UV 
source. 
Autophagy 
MCF7 cells expressing LC3 EGFP were utilized for examining 
the autophagy inducing capability. The stable cells were 
grown on glass bottom plates and upon reaching 70% 
confluency, the cells were subjected to the decided 
concentration (20, 40 and 80 µg/ml) of ND-DOX conjugate 
for 48 hrs. The cells were imaged for LC3 punctae formation 
by using 40x objective of a fluorescent microscope Nikon 
Tie. The images were captured using EMCCD camera, iXON 
889 using NIS element software. Ultimately, the green 
punctae signifies evidence for autophagy13-15. 
Cell cycle assay 
MCF7 cells were developed on the 24-well plates with 
indicated ND-DOX conjugate for 48 hrs. After 48 hrs, 
adherent and non-adherent cells were gathered and settled 
with 70% cold ethanol at 4°C overnight. Later the cells were 
trypsinized with one microgram/ml of Hoechst for 20 
minutes. The cells were rinsed and investigated by 
employing FACS. Then the cells were stimulated with 405m 
laser line and emission at 430/30 was collected for the DNA 
cell cycle study. 
Statistical analysis 
Final research outcome were showed as mean ± SD. All 
processes were performed thrice. 
RESULTS AND DISCUSSION 
The main objective behind the current study was to 
synthesize different ND-DOX conjugate for improved the 
targeting toward tumor cell as well as enhancing the potency 
of anticancer drug to provide maximum therapeutic effect. 
The surface of nanodiamond can be modified by many 
functional groups for providing higher stability of conjugate.  
Spectroscopic analysis (1H-NMR and FTIR) 
The 1H-NMR spectra of synthesized ND-DOX conjugate was 
illustrated in Figure 1. In 1H-NMR spectrum of ND-DOX 
conjugate different distinctive peak was obtained. the proton 
assignment of ND was obtained at 1.02 ppm (2H, S) and 1.04 
ppm (2H, S), shows presence of alkyl group, the peak at 2.17 
(1H, S) shows hydroxyl moiety (R-OH). The proton  
assignment of DOX was obtained at ppm 1.2  ppm (3H, S) 
and 3.5  ppm (3H, S), 5.9 (1H, S) and 7.8 (1H, S).  Beside of 
these proton assignment there are additional major peak 
was observed at 8.4 ppm (1H, S) and 8.9 ppm (1H, S), justify 
the presence of amide, which formed due to carbodiimide 
conjugation of carboxyl moiety of ND and amine group of 
DOX. All the proton assignment justifies the presence ND and 
DOX in the conjugate.  
 
 
Fig. 1 1H-NMR spectra of ND-DOX conjugate 
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The FTIR spectra of ND-DOX conjugate were shown in 
Figure 2. The conjugate ND-DOX, displayed distinctive peak 
at 727 cm-1, 857 cm-1, 927 cm-1, 2919 cm-1 shows C-H stretch, 
at 1285 cm-1 attribute to presence of C-O-C stretching, at 
1588 cm-1 has a predominantly mixed C=C stretch and C=O 
stretch, at 1650 cm-1 displayed the presence of C=O stretch, a 
broad spectrum at 3250 cm-1 shows the presence of N-H 
stretch. 
 
 
Fig. 2 FTIR spectra of ND-DOX conjugate 
Surface characteristics 
The surface characteristics like shape, size and texture of 
ND-DOX conjugate was examined by using atomic force 
microscopic technique (Alpha300RA AFM, WITec, Germany).   
 
Fig. 3 AFM image of ND-DOX conjugate 
The prepared ND-DOX conjugate having nanometric size 
range as monitored by AFM image Figure 3. The 
photomicrograph shows the uniform arrangement as well as 
similar height of the different ND-DOX conjugate. 
Summarizing, we have shown that the prepared ND-DOX 
conjugate displayed flake-like structure with preferred 
crystal orientation as well as its also clearly depicted that the 
particles are certainly not all the same. The 
photomicrograph from AFM, it was displayed that some 
particles show clearer sharp edges than others, according to 
these finding we assume, however, that sharp edges on that 
length scale would be quite reactive. 
Zeta potential determination, particle size analysis and 
drug entrapment proficiency 
According to the result depicted in Table 1, the particle size 
evaluation of ND-DOX conjugate was carried out using 
particle size analyzer and the particle size of ND-DOX 
conjugate were observed 59.2 nm. All the data obtained 
from particle size analysis, it was confirming that the ND-
DOX conjugate having nanometric size range. Zeta potential 
of ND-DOX conjugate was obtained to be -14.7 mV. The 
negative value of the zeta potential analysis of ND conjugate 
may be due to the carboxyl moiety of the nanodiamond. In 
the charge particle having increased zeta potential cause 
formation of more stable particles due to higher repulsive 
interaction. It was observed that the lower negative zeta 
potential may increase the stability of the system16. The 
loading efficiency of unconjugated (unbound) anticancer 
drug measured by HPLC and found to 94.3 ± 1.25%.
 
Table 1 Ingredients and concentration using in the formulation of ND-DOX conjugate 
Formulation Nanodiamond 
Concentration (mg) 
Distilled 
water (ml) 
DOX Acetone/ 
Ethanol (ml) 
Particle 
size (nm) 
Zeta 
potential 
% Drug loading 
Efficiency 
ND-DOX Conjugate 50 10 50 10 59.2nm -14.7mV 94.3±1.25 
  
In-vitro drug release pattern 
The sustained release nature of drug from ND-DOX 
conjugate system illustrated in Figure 4. It is recognized that 
well-organized release of drug from a drug delivery system 
is essential for therapeutic action of most of the anticancer 
drug conjugated formulations. Assimilation of acidic 
environment between the carrier and drug capable the 
liberation of an anticancer drug from the carrier (ND) into 
the cancer cell (having slightly acidic environment (pH 6.5)) 
then after endocytosis phase in the endosomes consisting pH 
range 5-6 and lysosomes (pH 4-5) of cancer cells. For this 
circumstances, the percentage release of drug from ND-DOX 
conjugate was performed at 37°C under simulated physi-
ological conditions (phosphate-buffered saline, pH 7.4) and 
an acidic environment (phosphate-buffered saline, pH 5.5, 
an acidic endosome environment and pH 6.5, a simulated 
tumor environment) to analyse the feasibility of ND-DOX 
conjugate as an drug delivery system for anticancer drug. As 
depicted in Figure 4 (a), the amount and rate of drug 
released from ND-DOX conjugate were dependent on the pH 
of the medium. ND-DOX conjugate displayed a rapid release 
pattern of anticancer drugs at pH 5.5 then pH 6.5 and then at 
pH 7.4. The release rate of drug from different ND-DOX 
conjugate after 96 hrs was found to be 35.5% at pH 5.5, 
whereas 24.6% was found at pH 6.5 and 16.2% of drug 
release was obtained at pH 7.4 correspondingly. Drug 
conjugated with ND via amide bond which is relatively more 
stable than physical absorption, thus slowing down the 
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release of anticancer drug from ND conjugate 17, 18. This is 
due to because of surface modification of ND via 
carbodiimide conjugation between of the carboxyl group of 
nanodiamond with the amine group of adipic acid 
dihydrazide and formation of crosslinked core-shell micelle, 
which having less solubility, may promote sustained 
release19. The data also has been suggested by various 
researchers, that acidic pH condition triggered the cleavage 
of amide bond20-23. The slow rate of anticancer drug (DOX) 
release from ND-DOX conjugate was calculated at pH 7.4, 
which mimics the physiological environment of the 
bloodstream and establishes that reduced amount of 
anticancer drugs, is liberated from conjugate in the blood 
circulation. It was assume that ND-DOX conjugate would 
adhere preferentially in the site of tumor cell via enhanced 
permeability and retention (EPR) effect. Figure 4 (b), also 
represents the release of unmodified anticancer drug (DOX), 
and the plateaus by approximately 30mins at pH 7.4, 6.5 and 
5.5 respectively, with a highest release of 98.5% at pH 7.4, 
the release 96.7% occurs at pH 6.5, and 94.8% at pH 5.5 
correspondingly. In contrast with ND-DOX conjugate, the 
free or unmodified anticancer drugs cause damage cells in a 
normal physiological environment, causing serious side 
effects. 
 
Fig. 4 (a) Drug release profile of ND-DOX conjugate 
 
Fig. 4 (b) Drug release profile of Unmodified (DOX) at 
different pH conditions 
Hemolytic toxicity study 
The hemotoxic effect of the prepared ND-DOX conjugate was 
estimated by hemolytic toxicity study. The ND-DOX 
conjugate exhibited hemolytic toxicity upto, 5.18±0.25%. 
Whereas the plain drug (DOX) represents hemolytic toxicity 
55.12±0.5%. There was decline in hemolytic toxicity by 
different ND-DOX conjugate in compare to plain drug, caused 
due to delayed release of encapsulated drug molecules in the 
nanodiamond conjugate. The repression of hemotoxicity of 
drug can be linked among other similar studies described 
previously 24. 
SRB (sulforhodamine B) assay 
The in-vitro cytotoxicity screening of ND-DOX conjugate in 
human breast cancer cell line (MCF-7) was established by 
SRB assay. The result obtained by the assay affirm dose 
dependent assessment of cytotoxicity in which the cellular 
bioavailability decreased with increasing the concentration 
of sample (ND-DOX conjugate and anticancer drugs DOX). 
The result of percentage growth inhibition of cell illustrated 
in Figure 5. Which revealed that higher concentration of 
sample ND-DOX conjugate inhibit the cell growth. 
Furthermore, the cell viability also gets declined with 
increase in the concentration of sample. ND-DOX conjugate 
formulations were experiential to be cytotoxic to a greater 
amount with the concentration between 10-80μg/ml. The 
Figure also states the cytotoxic effect of ND and unmodified 
anticancer drugs (DOX). The finding concluded that cytotoxic 
effect of optimized ND-DOX conjugate discovered to have 
greater inhibitory effect. 
 
Fig. 5 Cell-line study of ND-DOX against MCF-7 cells 
DNA fragmentation analysis 
To assess the apoptosis mechanism of tumor cell by ND-DOX 
conjugate, the DNA fragmentation analysis was performed. 
The cell was treated with ND-DOX conjugate for about 48 hrs 
and then isolates the DNA and analyzed by agarose gel 
electrophoresis. After 48 h incubation, the cell treated with 
drug showed high number of DNA ladder formation. In the 
result obtained from agarose gel electrophoresis of MCF-7 
cells, internucleosomal fragmentation was observed in MCF-
7 cells after 48 h of with ND-DOX conjugate treatment Figure 
6. These finding suggested that ND-DOX conjugate is an 
effective inducing agent of apoptosis against MCF-7 cell 
lines. 
 
Fig. 6 Agarose Gel Electrophoresis of ND-DOX conjugate 
nanocomplex (DNA Fragmentation study). A: Marker, B: 
Control, C: ND-DOX (100µM) 
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Autophagy analysis 
To investigate the dynamic behavior of autophagosomes 
noted the dynamic behaviors of LC3-positive vesicles 
present in the cell bodies and processes after transfection of 
EGFP-LC3, which is a standard procedure for 
autophagosome recognition. ND-DOX conjugate strongly 
induced autophagy in the cells as observed by the increase in 
a green dot like punctae. All the concentration displayed 
indication for autophagy Figure 7. 
 
Fig. 7 Autophagy Assay (a) Control; (b) cell treated with ND-DOX 
Cell cycle assay 
The antitumor mechanisms of prepared ND-DOX 
conjugates have consorted with mitosis, apoptosis and cell 
cycle arrest in the G2/M phase25. Consequently, the 
enhancement in G2/M phase arrest, signify the improved 
beneficial and therapeutic effect of conjugate. The effect of the 
arrest of G2/M phase (cell cycle) was investigated by the 
various range of concentration of conjugates against MCF-7 
cells (i.e. 20μg/ml, 40μg/ml and 80μg/ml). These conclusions 
suggested that ND-DOX conjugate at different concentration 
could encourage cell cycle arrest in MCF-7 cells. 
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